Skip to main content
Top
Published in: Journal of Gastroenterology 1/2017

01-01-2017 | Original Article—Liver, Pancreas, and Biliary Tract

Prediction of development of hepatocellular carcinoma using a new scoring system involving virtual touch quantification in patients with chronic liver diseases

Authors: Tomoko Aoki, Hiroko Iijima, Toshifumi Tada, Takashi Kumada, Takashi Nishimura, Chikage Nakano, Kyohei Kishino, Yoshihiro Shimono, Kazunori Yoh, Ryo Takata, Akio Ishii, Tomoyuki Takashima, Yoshiyuki Sakai, Nobuhiro Aizawa, Hiroki Nishikawa, Naoto Ikeda, Yoshinori Iwata, Hirayuki Enomoto, Seiichi Hirota, Jiro Fujimoto, Shuhei Nishiguchi

Published in: Journal of Gastroenterology | Issue 1/2017

Login to get access

Abstract

Background

This study aimed to establish a new scoring system that combined several risk factors, including virtual touch quantification (VTQ) values and fasting plasma glucose (FPG) levels, for predicting the development of hepatocellular carcinoma (HCC) in patients with chronic liver disease.

Methods

A total of 1808 chronic liver disease patients who underwent VTQ measurement were analyzed. Risk factors for developing HCC were selected by multivariate Cox proportional hazards models.

Results

VTQ (>1.33 m/s), FPG (≥110 mg/dl), sex (male), age (≥55 years), and α-fetoprotein (AFP) level (≥5 ng/ml) were independently selected as risk factors for HCC development by multivariate analysis. Using these parameters, we established a new scoring system (0 to 5 points), based on VTQ, FPG, sex, age, and AFP level, named VFMAP. As compared with the low VFMAP score group (0 or 1 point), the hazard ratio for the incidence of HCC was 17.37 [95 % confidence interval (CI), 2.35–128.40] in the intermediate-score group (2 or 3 points) and 66.82 (95 % CI, 9.01–495.80) in the high-score group (4 or 5 points). The area under the receiver operating characteristic curve of the VFMAP score for predicting HCC development within 5 years was 0.82 (95 % CI, 0.76–0.87), indicating a moderate diagnostic value. A VFMAP cutoff value of 3 excluded HCC within 5 years with a high negative predictive value (98.2 %).

Conclusion

The VFMAP score accurately predicted HCC in patients with chronic liver disease.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med. 1993;328:1797–801.CrossRefPubMed Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med. 1993;328:1797–801.CrossRefPubMed
3.
go back to reference Chang KC, Wu YY, Hung CH, et al. Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy. Br J Cancer. 2013;109:2481–8.CrossRefPubMedPubMedCentral Chang KC, Wu YY, Hung CH, et al. Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy. Br J Cancer. 2013;109:2481–8.CrossRefPubMedPubMedCentral
4.
go back to reference Oze T, Hiramatsu N, Yakushijin T, et al. Osaka Liver Forum. Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy. Clin Gastroenterol Hepatol. 2014;12:1186–95.CrossRefPubMed Oze T, Hiramatsu N, Yakushijin T, et al. Osaka Liver Forum. Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy. Clin Gastroenterol Hepatol. 2014;12:1186–95.CrossRefPubMed
5.
go back to reference Yamada R, Hiramatsu N, Oze T, et al. Osaka Liver Forum. Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection. J Gastroenterol. 2015;50:785–94.CrossRefPubMed Yamada R, Hiramatsu N, Oze T, et al. Osaka Liver Forum. Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection. J Gastroenterol. 2015;50:785–94.CrossRefPubMed
7.
go back to reference Castéra L, Nègre I, Samii K, et al. Pain experienced during percutaneous liver biopsy. Hepatology. 1999;30:1529–30.CrossRefPubMed Castéra L, Nègre I, Samii K, et al. Pain experienced during percutaneous liver biopsy. Hepatology. 1999;30:1529–30.CrossRefPubMed
8.
go back to reference Friedrich-Rust M, Wunder K, Kriener S, et al. Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. Radiology. 2009;252:595–604.CrossRefPubMed Friedrich-Rust M, Wunder K, Kriener S, et al. Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. Radiology. 2009;252:595–604.CrossRefPubMed
9.
go back to reference Lupsor M, Badea R, Stefanescu H, et al. Performance of a new elastographic method (ARFI technology) compared to unidimensional transient elastography in the noninvasive assessment of chronic hepatitis C. Preliminary results. J Gastrointestin Liver Dis. 2009;18:303–10.PubMed Lupsor M, Badea R, Stefanescu H, et al. Performance of a new elastographic method (ARFI technology) compared to unidimensional transient elastography in the noninvasive assessment of chronic hepatitis C. Preliminary results. J Gastrointestin Liver Dis. 2009;18:303–10.PubMed
10.
go back to reference Takahashi H, Ono N, Eguchi Y, et al. Evaluation of acoustic radiation force impulse elastography for fibrosis staging of chronic liver disease: a pilot study. Liver Int. 2010;30:538–45.CrossRefPubMed Takahashi H, Ono N, Eguchi Y, et al. Evaluation of acoustic radiation force impulse elastography for fibrosis staging of chronic liver disease: a pilot study. Liver Int. 2010;30:538–45.CrossRefPubMed
11.
go back to reference Friedrich-Rust M, Nierhoff J, Lupsor M, et al. Performance of acoustic radiation force impulse imaging for the staging of liver fibrosis: a pooled meta-analysis. J Viral Hepat. 2012;19:e212–9.CrossRefPubMed Friedrich-Rust M, Nierhoff J, Lupsor M, et al. Performance of acoustic radiation force impulse imaging for the staging of liver fibrosis: a pooled meta-analysis. J Viral Hepat. 2012;19:e212–9.CrossRefPubMed
12.
go back to reference Kircheis G, Sagir A, Vogt C, et al. Evaluation of acoustic radiation force impulse imaging for determination of liver stiffness using transient elastography as a reference. World J Gastroenterol. 2012;18:1077–84.CrossRefPubMedPubMedCentral Kircheis G, Sagir A, Vogt C, et al. Evaluation of acoustic radiation force impulse imaging for determination of liver stiffness using transient elastography as a reference. World J Gastroenterol. 2012;18:1077–84.CrossRefPubMedPubMedCentral
13.
go back to reference International Diabetes Federation. Diabetes atlas. International Diabetes Federation, 2013. International Diabetes Federation. Diabetes atlas. International Diabetes Federation, 2013.
15.
go back to reference Elkrief L, Chouinard P, Bendersky N, et al. Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C. Hepatology. 2014;60:823–31.CrossRefPubMed Elkrief L, Chouinard P, Bendersky N, et al. Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C. Hepatology. 2014;60:823–31.CrossRefPubMed
16.
17.
go back to reference The Japan Society of Hepatology. Surveillance algorithm and diagnostic algorithm for hepatocellular carcinoma: Clinical Practice Guidelines for Hepatocellular Carcinoma. Hepatology Res 2010; 40 Supplement s1: 6–7. The Japan Society of Hepatology. Surveillance algorithm and diagnostic algorithm for hepatocellular carcinoma: Clinical Practice Guidelines for Hepatocellular Carcinoma. Hepatology Res 2010; 40 Supplement s1: 6–7.
18.
go back to reference Shen L, Li JQ, Zeng MD, et al. Correlation between ultrasonographic and pathologic diagnosis of liver fibrosis due to chronic virus hepatitis. World J Gastroenterol. 2006;12:1292–5.CrossRefPubMedPubMedCentral Shen L, Li JQ, Zeng MD, et al. Correlation between ultrasonographic and pathologic diagnosis of liver fibrosis due to chronic virus hepatitis. World J Gastroenterol. 2006;12:1292–5.CrossRefPubMedPubMedCentral
19.
go back to reference Iacobellis A, Fusilli S, Mangia A, et al. Ultrasonographic and biochemical parameters in the non-invasive evaluation of liver fibrosis in hepatitis C virus chronic hepatitis. Aliment Pharmacol Ther. 2005;22:769–74.CrossRefPubMed Iacobellis A, Fusilli S, Mangia A, et al. Ultrasonographic and biochemical parameters in the non-invasive evaluation of liver fibrosis in hepatitis C virus chronic hepatitis. Aliment Pharmacol Ther. 2005;22:769–74.CrossRefPubMed
20.
go back to reference Caturelli E, Castellano L, Fusilli S, et al. Coarse nodular US pattern in hepatic cirrhosis: risk for hepatocellular carcinoma. Radiology. 2003;226:691–7.CrossRefPubMed Caturelli E, Castellano L, Fusilli S, et al. Coarse nodular US pattern in hepatic cirrhosis: risk for hepatocellular carcinoma. Radiology. 2003;226:691–7.CrossRefPubMed
21.
go back to reference Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518–26.CrossRefPubMed Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518–26.CrossRefPubMed
22.
go back to reference Akobeng AK. Understanding diagnostic tests 3: receiver operating characteristic curves. Acta Paediatr. 2007;96:644–7.CrossRefPubMed Akobeng AK. Understanding diagnostic tests 3: receiver operating characteristic curves. Acta Paediatr. 2007;96:644–7.CrossRefPubMed
25.
go back to reference Yamaoka K, Nakagawa T, Uno T. Application of Akaike’s information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm. 1978;6:165–75.CrossRefPubMed Yamaoka K, Nakagawa T, Uno T. Application of Akaike’s information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm. 1978;6:165–75.CrossRefPubMed
26.
go back to reference Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.CrossRefPubMed Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.CrossRefPubMed
27.
go back to reference American Diabetes Association. Standards of medical care in diabetes–2012. Diabetes Care. 2012;35(Suppl 1):S11–63. American Diabetes Association. Standards of medical care in diabetes–2012. Diabetes Care. 2012;35(Suppl 1):S11–63.
28.
go back to reference Sporea I, Bota S, Peck-Radosavljevic M, et al. Acoustic radiation force impulse elastography for fibrosis evaluation in patients with chronic hepatitis C: an international multicenter study. Eur J Radiol. 2012;81:4112–8.CrossRefPubMed Sporea I, Bota S, Peck-Radosavljevic M, et al. Acoustic radiation force impulse elastography for fibrosis evaluation in patients with chronic hepatitis C: an international multicenter study. Eur J Radiol. 2012;81:4112–8.CrossRefPubMed
29.
go back to reference Akima T, Tamano M, Hiraishi H. Liver stiffness measured by transient elastography is a predictor of hepatocellular carcinoma development in viral hepatitis. Hepatol Res. 2011;41:965–70.CrossRefPubMed Akima T, Tamano M, Hiraishi H. Liver stiffness measured by transient elastography is a predictor of hepatocellular carcinoma development in viral hepatitis. Hepatol Res. 2011;41:965–70.CrossRefPubMed
30.
go back to reference Jung KS, Kim SU, Ahn SH, et al. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology. 2011;53:885–94.CrossRefPubMed Jung KS, Kim SU, Ahn SH, et al. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology. 2011;53:885–94.CrossRefPubMed
31.
go back to reference Wang HM, Hung CH, Lu SN, et al. Liver stiffness measurement as an alternative to fibrotic stage in risk assessment of hepatocellular carcinoma incidence for chronic hepatitis C patients. Liver Int. 2013;33:756–61.CrossRefPubMed Wang HM, Hung CH, Lu SN, et al. Liver stiffness measurement as an alternative to fibrotic stage in risk assessment of hepatocellular carcinoma incidence for chronic hepatitis C patients. Liver Int. 2013;33:756–61.CrossRefPubMed
32.
go back to reference Masuzaki R, Tateishi R, Yoshida H, et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology. 2009;49:1954–61.CrossRefPubMed Masuzaki R, Tateishi R, Yoshida H, et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology. 2009;49:1954–61.CrossRefPubMed
33.
go back to reference Singh S, Fujii LL, Murad MH, et al. Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013;11:1573–84.CrossRefPubMedPubMedCentral Singh S, Fujii LL, Murad MH, et al. Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013;11:1573–84.CrossRefPubMedPubMedCentral
34.
go back to reference Sporea I, Sirli R, Bota S, et al. Is ARFI elastography reliable for predicting fibrosis severity in chronic HCV hepatitis? World J Radiol. 2011;28(3):188–93.CrossRef Sporea I, Sirli R, Bota S, et al. Is ARFI elastography reliable for predicting fibrosis severity in chronic HCV hepatitis? World J Radiol. 2011;28(3):188–93.CrossRef
35.
go back to reference Rizzo L, Calvaruso V, Cacopardo B, et al. Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C. Am J Gastroenterol. 2011;106:2112–20.CrossRefPubMed Rizzo L, Calvaruso V, Cacopardo B, et al. Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C. Am J Gastroenterol. 2011;106:2112–20.CrossRefPubMed
36.
go back to reference Tsilidis KK, Kasimis JC, Lopez DS, et al. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ. 2015;350:g7607.CrossRefPubMed Tsilidis KK, Kasimis JC, Lopez DS, et al. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ. 2015;350:g7607.CrossRefPubMed
37.
go back to reference de Groot M, Anderson R, Freedland KE, et al. Association of depression and diabetes complications: a meta-analysis. Psychosom Med. 2001;63:619–30.CrossRefPubMed de Groot M, Anderson R, Freedland KE, et al. Association of depression and diabetes complications: a meta-analysis. Psychosom Med. 2001;63:619–30.CrossRefPubMed
38.
go back to reference Koh WP, Wang R, Jin A, et al. Diabetes mellitus and risk of hepatocellular carcinoma: findings from the Singapore Chinese Health Study. Br J Cancer. 2013;108:1182–8.CrossRefPubMedPubMedCentral Koh WP, Wang R, Jin A, et al. Diabetes mellitus and risk of hepatocellular carcinoma: findings from the Singapore Chinese Health Study. Br J Cancer. 2013;108:1182–8.CrossRefPubMedPubMedCentral
39.
go back to reference Aizawa N, Enomoto H, Imanishi H, et al. Elevation of the glycated albumin to glycated hemoglobin ratio during the progression of hepatitis C virus related liver fibrosis. World J Hepatol. 2012;4:11–7.CrossRefPubMedPubMedCentral Aizawa N, Enomoto H, Imanishi H, et al. Elevation of the glycated albumin to glycated hemoglobin ratio during the progression of hepatitis C virus related liver fibrosis. World J Hepatol. 2012;4:11–7.CrossRefPubMedPubMedCentral
40.
go back to reference Hosaka T, Suzuki F, Kobayashi M, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 2013;58:98–107.CrossRefPubMed Hosaka T, Suzuki F, Kobayashi M, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 2013;58:98–107.CrossRefPubMed
41.
go back to reference Kumada T, Toyoda H, Tada T, et al. Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis. J Hepatol. 2013;58:427–33.CrossRefPubMed Kumada T, Toyoda H, Tada T, et al. Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis. J Hepatol. 2013;58:427–33.CrossRefPubMed
42.
go back to reference Kasahara A, Hayashi N, Mochizuki K, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology. 1998;27:1394–402. Kasahara A, Hayashi N, Mochizuki K, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology. 1998;27:1394–402.
Metadata
Title
Prediction of development of hepatocellular carcinoma using a new scoring system involving virtual touch quantification in patients with chronic liver diseases
Authors
Tomoko Aoki
Hiroko Iijima
Toshifumi Tada
Takashi Kumada
Takashi Nishimura
Chikage Nakano
Kyohei Kishino
Yoshihiro Shimono
Kazunori Yoh
Ryo Takata
Akio Ishii
Tomoyuki Takashima
Yoshiyuki Sakai
Nobuhiro Aizawa
Hiroki Nishikawa
Naoto Ikeda
Yoshinori Iwata
Hirayuki Enomoto
Seiichi Hirota
Jiro Fujimoto
Shuhei Nishiguchi
Publication date
01-01-2017
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 1/2017
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-016-1228-7

Other articles of this Issue 1/2017

Journal of Gastroenterology 1/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.